CalciMedica, Inc. (NASDAQ:CALC) Major Shareholder Sanderling Venture Partners Vi Acquires 86,867 Shares

CalciMedica, Inc. (NASDAQ:CALC) major shareholder Sanderling Venture Partners Vi bought 86,867 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were acquired at an average price of $3.75 per share, with a total value of $325,751.25. Following the purchase, the insider now owns 814,300 shares in the company, valued at $3,053,625. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

CalciMedica Stock Performance

Shares of CALC opened at $3.50 on Friday. The company has a 50-day simple moving average of $4.20 and a 200-day simple moving average of $4.61. CalciMedica, Inc. has a 52 week low of $2.68 and a 52 week high of $8.38. The firm has a market capitalization of $37.63 million, a P/E ratio of -2.50 and a beta of 1.30.

CalciMedica (NASDAQ:CALC) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.03. As a group, equities analysts forecast that CalciMedica, Inc. will post -2.21 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lowered their price objective on shares of CalciMedica from $20.00 to $16.00 and set a “buy” rating on the stock in a research note on Monday.

Institutional Inflows and Outflows

An institutional investor recently raised its position in CalciMedica stock. Atria Investments Inc increased its stake in shares of CalciMedica, Inc. (NASDAQ:CALC) by 136.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,503 shares of the company’s stock after buying an additional 15,296 shares during the quarter. Atria Investments Inc owned 0.25% of CalciMedica worth $117,000 at the end of the most recent reporting period.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.